Literature DB >> 16849373

Effects of changing clinical practice on costs and outcomes of percutaneous coronary intervention between 1998 and 2002.

M A Denvir1, A J Lee, J Rysdale, R J Prescott, H Eteiba, I R Starkey, J P Pell, A Walker.   

Abstract

AIM: To assess the effect of changing clinical practice on the costs and outcomes of percutaneous coronary intervention (PCI) between 1998 and 2002.
SETTING: Two tertiary interventional centres. PATIENTS: Consecutive patients undergoing PCI over a 12-month period between 1998 and 2002.
DESIGN: Comparative observational study of costs and 12-month clinical outcomes of consecutive PCI procedures in 1998 (n = 1047) and 2002 (n = 1346). Clinical data were recorded in the Scottish PCI register. Repeat PCI, coronary artery bypass graft and mortality were obtained by record linkage. Costs of equipment were calculated using a computerised bar-code system and standard National Health Service reference costs.
RESULTS: Between 1998 and 2002, the use of bare metal stents increased from 44% to 81%, and the use of glycoprotein IIB/IIIA inhibitors increased from 0% to 14% of cases. During this time, a significant reduction was observed in repeat target-vessel PCI (from 8.4% to 5.1%, p = 0.001), any repeat PCI (from 11.7% to 9.2%, p = 0.05) and any repeat revascularisation (from 15.1% to 11.3%, p = 0.009) within 12 months. Significantly higher cost per case in 2002 compared with 1998 (mean (standard deviation) 2311 pounds (1158) v 1785 pounds (907), p<0.001) was mainly due to increased contribution from bed-day costs in 2002 (45.0% (16.3%) v 26.2% (12.6%), p = 0.01) associated with non-elective cases spending significantly longer in hospital (6.22 (4.3) v 4.6 (4.3) days, p = 0.01).
CONCLUSIONS: Greater use of stents and glycoprotein IIb/IIIa inhibitors between 1998 and 2002 has been accompanied by a marked reduction in the need for repeat revascularisation. Longer duration of hospital stay for non-elective cases is mainly responsible for increasing costs. Strategies to reduce the length of stay could considerably reduce the costs of PCI.

Entities:  

Mesh:

Year:  2006        PMID: 16849373      PMCID: PMC1861374          DOI: 10.1136/hrt.2006.090134

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  18 in total

1.  Reducing costs and improving outcomes of percutaneous coronary interventions.

Authors:  Mauro Moscucci; David W Muller; Charles M Watts; Vinita Bahl; Eric R Bates; Steven W Werns; Eva Kline-Rogers; Dean Karavite; Kim A Eagle
Journal:  Am J Manag Care       Date:  2003-05       Impact factor: 2.229

2.  Percutaneous coronary interventions in Europe 1992-2001.

Authors:  Mario Togni; Florian Balmer; Dorothy Pfiffner; Willibald Maier; Andreas M Zeiher; Bernhard Meier
Journal:  Eur Heart J       Date:  2004-07       Impact factor: 29.983

3.  Comparing performance between coronary intervention centres requires detailed case-mix adjusted analysis.

Authors:  M A Denvir; A J Lee; J Rysdale; R J Prescott; H Eteiba; A Walker; I R Starkey; J P Pell
Journal:  J Public Health (Oxf)       Date:  2004-06       Impact factor: 2.341

4.  Coronary stenting: costly or cost-effective?

Authors:  D J Cohen; D S Baim
Journal:  J Invasive Cardiol       Date:  1995       Impact factor: 2.022

5.  Back to the future?

Authors:  Richard Q Lewis
Journal:  BMJ       Date:  2004-10-23

6.  Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention.

Authors:  Patricia A Cowper; Krishna Udayakumar; Michael H Sketch; Eric D Peterson
Journal:  J Am Coll Cardiol       Date:  2005-02-01       Impact factor: 24.094

7.  Clinical and economic effects of coronary restenosis after percutaneous coronary intervention in a managed care population.

Authors:  Mary Ann Clark; Ameet Bakhai; Elise M Pelletier; David J Cohen
Journal:  Manag Care       Date:  2005-04

8.  Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.

Authors:  Keith A A Fox; Shamir R Mehta; Ron Peters; Feng Zhao; Nasser Lakkis; Bernard J Gersh; Salim Yusuf
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

9.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.

Authors:  P W Serruys; P de Jaegere; F Kiemeneij; C Macaya; W Rutsch; G Heyndrickx; H Emanuelsson; J Marco; V Legrand; P Materne
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

10.  Market reform in New Jersey and the effect on mortality from acute myocardial infarction.

Authors:  Kevin G M Volpp; Sankey V Williams; Joel Waldfogel; Jeffrey H Silber; J Sanford Schwartz; Mark V Pauly
Journal:  Health Serv Res       Date:  2003-04       Impact factor: 3.402

View more
  1 in total

1.  Comparison of the treatment practice and hospitalization cost of percutaneous coronary intervention between a teaching hospital and a general hospital in Malaysia: A cross sectional study.

Authors:  Kun Yun Lee; Wan Azman Wan Ahmad; Ee Vien Low; Siow Yen Liau; Lawrence Anchah; Syuhada Hamzah; Houng-Bang Liew; Rosli B Mohd Ali; Omar Ismail; Tiong Kiam Ong; Mas Ayu Said; Maznah Dahlui
Journal:  PLoS One       Date:  2017-09-05       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.